Trastuzumab beyond progression: is the risk of cardiac toxicity really not increased?

MeSH terms

• Antibodies, Monoclonal / adverse effects*
• Antibodies, Monoclonal / therapeutic use
• Antibodies, Monoclonal, Humanized
• Antineoplastic Agents / adverse effects*
• Antineoplastic Agents / therapeutic use
• Breast Neoplasms / drug therapy*
• Female
• Heart Diseases / chemically induced*
• Humans
• Risk Factors
• Sample Size
• Trastuzumab